vs
Corpay（CPAY）与瑞思迈（RMD）财务数据对比。点击上方公司名可切换其他公司
瑞思迈的季度营收约是Corpay的1.1倍（$1.4B vs $1.2B），瑞思迈净利率更高（27.6% vs 21.2%，领先6.4%），Corpay同比增速更快（20.7% vs 11.0%），Corpay自由现金流更多（$760.3M vs $311.2M），过去两年Corpay的营收复合增速更高（15.5% vs 9.0%）
Corpay总部位于美国佐治亚州亚特兰大，是专业的支付与支出管理服务提供商，旗下系统及服务可帮助客户高效管控采购、支付全流程的相关费用，核心业务覆盖车辆相关支出、住宿支出及企业支付三大领域。
瑞思迈是一家起源于澳大利亚、总部位于美国加利福尼亚州圣迭戈的医疗设备企业，主打可接入云端的呼吸类医疗设备，用于治疗睡眠呼吸暂停、慢性阻塞性肺病等呼吸道疾病，新冠疫情期间曾大量生产呼吸机等设备助力患者救治。
CPAY vs RMD — 直观对比
营收规模更大
RMD
是对方的1.1倍
$1.2B
营收增速更快
CPAY
高出9.7%
11.0%
净利率更高
RMD
高出6.4%
21.2%
自由现金流更多
CPAY
多$449.1M
$311.2M
两年增速更快
CPAY
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $1.4B |
| 净利润 | $264.5M | $392.6M |
| 毛利率 | — | 61.8% |
| 营业利润率 | 45.2% | 34.6% |
| 净利率 | 21.2% | 27.6% |
| 营收同比 | 20.7% | 11.0% |
| 净利润同比 | 7.5% | 13.9% |
| 每股收益（稀释后） | $3.74 | $2.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CPAYRMD
| Q4 25 | $1.2B | $1.4B | ||
| Q3 25 | $1.2B | $1.3B | ||
| Q2 25 | $1.1B | $1.3B | ||
| Q1 25 | $1.0B | $1.3B | ||
| Q4 24 | $1.0B | $1.3B | ||
| Q3 24 | $1.0B | $1.2B | ||
| Q2 24 | $975.7M | $1.2B | ||
| Q1 24 | $935.3M | $1.2B |
净利润CPAYRMD
| Q4 25 | $264.5M | $392.6M | ||
| Q3 25 | $277.9M | $348.5M | ||
| Q2 25 | $284.2M | $379.7M | ||
| Q1 25 | $243.2M | $365.0M | ||
| Q4 24 | $246.0M | $344.6M | ||
| Q3 24 | $276.4M | $311.4M | ||
| Q2 24 | $251.6M | $292.2M | ||
| Q1 24 | $229.8M | $300.5M |
毛利率CPAYRMD
| Q4 25 | — | 61.8% | ||
| Q3 25 | — | 61.5% | ||
| Q2 25 | — | 60.8% | ||
| Q1 25 | — | 59.3% | ||
| Q4 24 | — | 58.6% | ||
| Q3 24 | — | 58.6% | ||
| Q2 24 | — | 58.5% | ||
| Q1 24 | — | 57.9% |
营业利润率CPAYRMD
| Q4 25 | 45.2% | 34.6% | ||
| Q3 25 | 44.6% | 33.4% | ||
| Q2 25 | 43.5% | 33.7% | ||
| Q1 25 | 42.5% | 33.0% | ||
| Q4 24 | 47.2% | 32.5% | ||
| Q3 24 | 45.5% | 31.6% | ||
| Q2 24 | 44.4% | 31.2% | ||
| Q1 24 | 42.5% | 31.3% |
净利率CPAYRMD
| Q4 25 | 21.2% | 27.6% | ||
| Q3 25 | 23.7% | 26.1% | ||
| Q2 25 | 25.8% | 28.2% | ||
| Q1 25 | 24.2% | 28.3% | ||
| Q4 24 | 23.8% | 26.9% | ||
| Q3 24 | 26.9% | 25.4% | ||
| Q2 24 | 25.8% | 23.9% | ||
| Q1 24 | 24.6% | 25.1% |
每股收益（稀释后）CPAYRMD
| Q4 25 | $3.74 | $2.68 | ||
| Q3 25 | $3.91 | $2.37 | ||
| Q2 25 | $3.98 | $2.58 | ||
| Q1 25 | $3.40 | $2.48 | ||
| Q4 24 | $3.43 | $2.34 | ||
| Q3 24 | $3.90 | $2.11 | ||
| Q2 24 | $3.52 | $1.97 | ||
| Q1 24 | $3.12 | $2.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.4B | $1.4B |
| 总债务越低越好 | $10.0B | $403.9M |
| 股东权益账面价值 | $3.9B | $6.3B |
| 总资产 | $26.4B | $8.5B |
| 负债/权益比越低杠杆越低 | 2.58× | 0.06× |
8季度趋势，按日历期对齐
现金及短期投资CPAYRMD
| Q4 25 | $2.4B | $1.4B | ||
| Q3 25 | $2.0B | $1.4B | ||
| Q2 25 | $2.2B | $1.2B | ||
| Q1 25 | $1.6B | $932.7M | ||
| Q4 24 | $1.6B | $521.9M | ||
| Q3 24 | $1.3B | $426.4M | ||
| Q2 24 | $1.4B | $238.4M | ||
| Q1 24 | $1.3B | $237.9M |
总债务CPAYRMD
| Q4 25 | $10.0B | $403.9M | ||
| Q3 25 | $8.1B | $408.7M | ||
| Q2 25 | $8.1B | $658.4M | ||
| Q1 25 | $8.2B | $663.1M | ||
| Q4 24 | $8.0B | $662.9M | ||
| Q3 24 | — | $667.6M | ||
| Q2 24 | — | $697.3M | ||
| Q1 24 | — | $997.0M |
股东权益CPAYRMD
| Q4 25 | $3.9B | $6.3B | ||
| Q3 25 | $4.1B | $6.1B | ||
| Q2 25 | $3.9B | $6.0B | ||
| Q1 25 | $3.5B | $5.5B | ||
| Q4 24 | $3.1B | $5.3B | ||
| Q3 24 | $3.1B | $5.2B | ||
| Q2 24 | $2.8B | $4.9B | ||
| Q1 24 | $3.3B | $4.6B |
总资产CPAYRMD
| Q4 25 | $26.4B | $8.5B | ||
| Q3 25 | $19.7B | $8.3B | ||
| Q2 25 | $20.4B | $8.2B | ||
| Q1 25 | $18.5B | $7.6B | ||
| Q4 24 | $18.0B | $7.1B | ||
| Q3 24 | $17.6B | $7.2B | ||
| Q2 24 | $16.2B | $6.9B | ||
| Q1 24 | $15.8B | $6.8B |
负债/权益比CPAYRMD
| Q4 25 | 2.58× | 0.06× | ||
| Q3 25 | 1.99× | 0.07× | ||
| Q2 25 | 2.07× | 0.11× | ||
| Q1 25 | 2.37× | 0.12× | ||
| Q4 24 | 2.56× | 0.13× | ||
| Q3 24 | — | 0.13× | ||
| Q2 24 | — | 0.14× | ||
| Q1 24 | — | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $812.7M | $339.7M |
| 自由现金流经营现金流 - 资本支出 | $760.3M | $311.2M |
| 自由现金流率自由现金流/营收 | 60.9% | 21.9% |
| 资本支出强度资本支出/营收 | 4.2% | 2.0% |
| 现金转化率经营现金流/净利润 | 3.07× | 0.87× |
| 过去12个月自由现金流最近4个季度 | $1.3B | $1.8B |
8季度趋势，按日历期对齐
经营现金流CPAYRMD
| Q4 25 | $812.7M | $339.7M | ||
| Q3 25 | $-378.9M | $457.3M | ||
| Q2 25 | $1.1B | $538.8M | ||
| Q1 25 | $-74.2M | $578.7M | ||
| Q4 24 | $648.7M | $308.6M | ||
| Q3 24 | $400.8M | $325.5M | ||
| Q2 24 | $540.9M | $440.1M | ||
| Q1 24 | $350.2M | $402.0M |
自由现金流CPAYRMD
| Q4 25 | $760.3M | $311.2M | ||
| Q3 25 | $-429.8M | $414.4M | ||
| Q2 25 | $1.1B | $508.2M | ||
| Q1 25 | $-118.9M | $557.9M | ||
| Q4 24 | $604.6M | $288.0M | ||
| Q3 24 | $355.0M | $307.7M | ||
| Q2 24 | $496.8M | $415.2M | ||
| Q1 24 | $309.0M | $380.8M |
自由现金流率CPAYRMD
| Q4 25 | 60.9% | 21.9% | ||
| Q3 25 | -36.7% | 31.0% | ||
| Q2 25 | 98.7% | 37.7% | ||
| Q1 25 | -11.8% | 43.2% | ||
| Q4 24 | 58.4% | 22.5% | ||
| Q3 24 | 34.5% | 25.1% | ||
| Q2 24 | 50.9% | 33.9% | ||
| Q1 24 | 33.0% | 31.8% |
资本支出强度CPAYRMD
| Q4 25 | 4.2% | 2.0% | ||
| Q3 25 | 4.3% | 3.2% | ||
| Q2 25 | 4.8% | 2.3% | ||
| Q1 25 | 4.5% | 1.6% | ||
| Q4 24 | 4.3% | 1.6% | ||
| Q3 24 | 4.4% | 1.5% | ||
| Q2 24 | 4.5% | 2.0% | ||
| Q1 24 | 4.4% | 1.8% |
现金转化率CPAYRMD
| Q4 25 | 3.07× | 0.87× | ||
| Q3 25 | -1.36× | 1.31× | ||
| Q2 25 | 4.01× | 1.42× | ||
| Q1 25 | -0.30× | 1.59× | ||
| Q4 24 | 2.64× | 0.90× | ||
| Q3 24 | 1.45× | 1.05× | ||
| Q2 24 | 2.15× | 1.51× | ||
| Q1 24 | 1.52× | 1.34× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPAY
| Vehicle Payments | $572.9M | 46% |
| Corporate Payments | $480.8M | 39% |
| Lodging Payments | $112.5M | 9% |
| Other Operating Segments | $82.1M | 7% |
RMD
| Sleep And Breathing Health | $1.3B | 88% |
| Residential Care Software | $166.9M | 12% |
